Showing 15 posts of 111 posts found.


Eisai withdraws application for neurodegenerative-disease drug in Japan

March 22, 2016
Manufacturing and Production, Research and Development Eisai, mecobalamin, neurodegenerative disease

Pharma major Eisai (TYO: 4523) on Tuesday said the Japanese regulators have stalled the approval of its drug to treat …


Eisai slams new Cancer Drugs Fund for delaying patient access

February 26, 2016
Research and Development, Sales and Marketing Cancer Drugs Fund, Eisai, Lenvima

Eisai has aimed strong criticism at NHS England for its approval of reforms to the Cancer Drugs Fund, calling the …

Eisai logo

FDA grants Eisai’s Lenvima priority review for kidney cancer

January 19, 2016
Manufacturing and Production Breakthrough Therapy Designation, Eisai, FDA, Kidney cancer, Lenvima, lenvatinib, priority review, renal cell carcinoma

The FDA has accepted Eisai’s supplemental New Drug Application (sNDA) for its anti-cancer agent Lenvima for use in the treatment …


Eisai submits new cancer combo to EMA for approval

January 12, 2016
Sales and Marketing Afinitor, EMA, Eisai, Lenvima, MAA, Novartis, everolimus, lenvatinib

Eisai has submitted a new Marketing Authorisation Application to the EMA for the combination of Lenvima and Novartis’ Afinitor for …


Eisai’s Halaven shown to restrict further cancer metastasis

December 11, 2015
Research and Development, Sales and Marketing Eisai, Halaven, Merck, keytruda

New data presented by Eisai supports the previously shown ability of Halaven (eribulin) to reverse epithelial-to-mesenchymal transition, the process by …

Eisai image

Eisai earns FDA nod for Fycompa

June 22, 2015
Sales and Marketing Eisai, FDA, Fycompa

The FDA has expanded the patient groups for whom Eisai’s epilepsy drug Fycompa is available to include people who have …

Eisai image

Eisai seeks new ALS drug approval

May 28, 2015
Sales and Marketing Eisai, Japan, als, mecobalamin

Eisai is hoping that existing neurology drug mecobalamin can be a new option for the difficult-to-treat condition amyotrophic lateral sclerosis …


Eisai epilepsy drug sees EMA nod

May 27, 2015
Research and Development, Sales and Marketing Eisai, Fycompa, ema. epilepsy

Eisai’s UK subsidiary has received a positive opinion from the European Medicines Agency for using Fycompa for the adjunctive treatment …

Bayer image

Bayer wins Cancer Drugs Fund appeal

May 22, 2015
Sales and Marketing Bayer, CDF, Cancer Drugs Fund, Eisai, NHS, lilly

Bayer is the only company to win its appeal to NHS England in the latest round of Cancer Drugs Fund …

Eisai image

Eisai cuts 25% of US staff

April 10, 2015
Medical Communications, Research and Development, Sales and Marketing Daiichi, Eisai, US, cuts, layoffs, reorganisation, staff

Eisai’s US business is offloading around 200 jobs as part of some restructuring to create a more ‘efficient and focussed …

EMA image

EMA committee recommends five drugs for approval

March 30, 2015
Sales and Marketing Boehringer, CHMP, EMA, Eisai, Europe, Gardasil, Lenvima, Merck, akynzio, jardiance, lilly

Cancer and diabetes treatments are among those given the go ahead in the latest round of approvals by the EMA. …

Eisai image

Eisai Alzheimer’s drug to see China review

March 4, 2015
Sales and Marketing Alzheimer's, Aricept, China, Eisai, donepezil hydrochloride

Alzheimer’s drug Aricept from Eisai has been accepted for review in China to treat patients with the most severe form …

Eisai image

Eisai cancer drug performs in sarcoma disease

February 26, 2015
Sales and Marketing Cancer, Eisai, Halaven, eribulin, sarcoma, tumour

Eisai’s cancer drug Halaven met its primary endpoint and demonstrated overall survival benefit in two distinct solid tumour types in …


FDA approves Eisai thyroid drug, fast-tracks Novartis heart pill

February 16, 2015
Sales and Marketing Eisai, FDA, LCZ696, Lenvima, Novartis, heart, lenvatinib, thyroid

The FDA has approved Eisai’s thyroid cancer drug Lenvima and also granted Novartis heart pill LCZ696 a priority review.  Lenvima …

Eisai image

Eisai: Fycompa decision ‘deeply regrettable’

November 11, 2014
Research and Development, Sales and Marketing Eisai, Fycompa, Germany, epilepsy, gba, perampanel

Eisai has lashed out at a major German health assessment body, calling its stance on first-in-class epilepsy treatment Fycompa ‘deeply …

Latest content